PROCEPT BioRobotics Corporation (PRCT) is expected to deliver a year-over-year increase in earnings on higher revenues when it reports results for the quarter ended September 2024. This widely-known consensus outlook gives a good sense of the company's earnings picture, but how the actual results compare to these estimates is a powerful factor that could impact its near-term stock price.The earnings report, which is expected to be released on October 28, 2024, might help the stock move higher if these key n ...

A Prospective, Randomized, Multicenter Study Assessing the Safety and Efficacy of Aquablation Therapy in Men with Grade Group 1 to 3 Localized Prostate Cancer Represents Potential Paradigm Shift in How Urologists Might Treat Localized Prostate Cancer SAN JOSE, Calif., Oct. 07, 2024 (GLOBE NEWSWIRE) -- PROCEPT BioRobotics® Corporation (Nasdaq: PRCT) (the "Company"), a surgical robotics company focused on advancing patient care by developing transformative solutions in urology, today announced the U.S. Food a ...

SAN JOSE, Calif., Aug. 28, 2024 (GLOBE NEWSWIRE) -- PROCEPT BioRobotics® (Nasdaq: PRCT) (the "Company"), a surgical robotics company focused on advancing patient care by developing transformative solutions in urology, today announced that members of management will present at the upcoming 2024 Wells Fargo Healthcare Conference in Boston, Massachusetts. Management is scheduled to present on Wednesday, September 4 at 1:30 p.m. Eastern Time. A live webcast of each event, as well as an archived recording, will ...

1 IF D H HT T 100 - 100 1 i T 1 Pgiam/iStock via Getty Images Investment update Following my last publication on PROCEPT BioRobotics Corporation (NASDAQ:PRCT) around 12 months ago, the stock is +146% and now trades above $78/share. The most recent catalyst was the FDA's 510(k) approval of the company's HYDROS Robotic System ("Hydros"), extending PRCT's offerings in benign prostatic hypertrophy ("BPH") even further. Investors have bought PRCT on the news + the stock gapped above a key ~$70/share technical le ...

Company Update - PROCEPT BioRobotics announced FDA 510(k) clearance for its next-generation HYDROS Robotic System, marking a significant milestone in the adoption of Aquablation therapy [1] - The HYDROS Robotic System incorporates major technological innovations developed over years of research and is expected to drive the company's next growth phase [2] - The system is designed to enhance productivity, improve surgeon experience, and deliver precise, consistent treatment plans, with a full market release anticipated within the current quarter [4] Product Features - The HYDROS Robotic System features FirstAssist AI treatment planning, advanced image guidance, and robotic resection, aiming to provide superior clinical outcomes [5] - It integrates digital cystoscopy, next-generation ultrasound imaging, and dual high-definition touchscreens for improved anatomy visualization [6] - The system uses a heat-free waterjet to remove obstructive tissue while protecting vital structures, ensuring efficient and predictable execution across various prostate sizes [7] Industry Outlook - The global BPH treatment devices market was valued at $1.42 billion in 2022 and is projected to grow at a CAGR of 8.9% from 2023 to 2030 [8] - Growth is driven by technological advancements, increasing prevalence of urological illnesses, and rising patient awareness of minimally invasive treatment options [8][9] - Demand for innovative, minimally invasive technologies like Aquablation therapy is expected to rise due to fewer side effects and faster recovery times compared to traditional surgical methods [9] Stock Performance - PRCT's shares have gained 99% year-to-date, significantly outperforming the industry's 9.4% rise and the S&P 500's 17.8% increase [10]

PROCEPT BioRobotics (PRCT) , a surgical robotics company, recently achieved a significant milestone as it received FDA 510(k) clearance for its HYDROS Robotic System. This next-generation platform is set to revolutionize urological care by offering advanced features designed to enhance efficiency, precision and clinical outcomes. This latest regulatory clearance is expected to help PROCEPT expand in the specialized field of Aquablation therapy within transformative urological solutions. The therapy is, of l ...

SAN JOSE, Calif., Aug. 21, 2024 (GLOBE NEWSWIRE) -- PROCEPT BioRobotics® Corporation (Nasdaq: PRCT) (the "Company"), a surgical robotics company focused on advancing patient care by developing transformative solutions in urology, today announced FDA 510(k) clearance of its next-generation platform, the HYDROS™ Robotic System. Leveraging insights from over 50,000 procedures, HYDROS features FirstAssist AI™ treatment planning, advanced image guidance, robotic resection, and a streamlined workflow. HYDROS is d ...

PROCEPT BioRobotics Today | --- | --- | |----------------------|-------| | | | | | | | | | | PRCT | | | PROCEPT BioRobotics | | | $64.60 | | | +1.27 (+2.01%) | | | 52-Week Range $24.83 | | | ▼ | | | $77.00 | | | Price Target $66.00 | | | Add to Watchlist | | Surgical robotics company PROCEPT BioRobotics Co. NASDAQ: PRCT developed the AquaBeam Robotic System for the treatment of benign prostatic hyperplasia (BPH) among aging men. The company went public during the special purpose acquisition company (SPAC) m ...

PROCEPT BioRobotics Corporation (NASDAQ:PRCT) Q2 2024 Earnings Conference Call August 1, 2024 4:30 AM ET Company Participants Matt Bacso - Vice President, Investor Relations Reza Zadno - President & Chief Executive Officer Sham Shiblaq - Executive VP, Chief Commercial Officer Kevin Waters - Executive VP, Chief Financial Officer Conference Call Participants Craig Bijou - Bank of America Matthew O'Brien - Piper Sandler Richard Newitter - Truist Brandon Vasquez - William Blair Joshua Jennings - TD Cowen Dino W ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 001-40797 PROCEPT BioRobotics Corporation (Exact name of registrant as specified in its charter) Delaware 26-0199180 (State or other ...